| 2.435 0.065 (2.74%) | 02-03 13:33 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.32 | 1-year : | 3.88 |
| Resists | First : | 2.84 | Second : | 3.32 |
| Pivot price | 1.95 |
|||
| Supports | First : | 1.76 | Second : | 1.09 |
| MAs | MA(5) : | 2.45 |
MA(20) : | 1.86 |
| MA(100) : | 1.28 |
MA(250) : | 0.96 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 74.3  |
D(3) : | 80.5 |
| RSI | RSI(14): 73.1 |
|||
| 52-week | High : | 2.84 | Low : | 0.49 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CNTX ] has closed below upper band by 20.2%. Bollinger Bands are 300.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.73 - 2.75 | 2.75 - 2.75 |
| Low: | 2.22 - 2.24 | 2.24 - 2.25 |
| Close: | 2.35 - 2.37 | 2.37 - 2.39 |
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Sat, 31 Jan 2026
Context Therapeutics (NASDAQ:CNTX) Upgraded to Hold at Wall Street Zen - MarketBeat
Sat, 24 Jan 2026
Context Therapeutics Insiders May Regret Not Buying More, Market Cap Hits US$151m - Sahm
Fri, 16 Jan 2026
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Mon, 12 Jan 2026
Context Therapeutics Inc. (NASDAQ:CNTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Thu, 08 Jan 2026
Context Therapeutics Highlights T Cell Engager Pipeline Strategy - TipRanks
Mon, 05 Jan 2026
After-Hours Biotech Rally: Alumis, Genelux, Bright Minds, Context Therapeutics Post Big Gains - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 92 (M) |
| Shares Float | 40 (M) |
| Held by Insiders | 1.1 (%) |
| Held by Institutions | 75.6 (%) |
| Shares Short | 516 (K) |
| Shares Short P.Month | 497 (K) |
| EPS | -0.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.8 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -22.9 % |
| Return on Equity (ttm) | -33.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.33 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -22 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -9.78 |
| PEG Ratio | 0 |
| Price to Book value | 3.05 |
| Price to Sales | 0 |
| Price to Cash Flow | -10.06 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|